专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

CN109022391A 血小板激活因子乙酰水解酶IB亚基γ突变蛋白及其应用无效
公开(公告)号：CN109022391A
公开(公告)日：2018-12-18
申请号：CN201810741597.3
申请日：2018-07-09
申请人：天津市湖滨盘古基因科学发展有限公司
发明人：张耀洲 , 吴玉乾 , 冯建华 , 李冬梅 , 张树军 , 陈玉皎 , 王文雅
IPC分类号： C12N9/18 , C12N15/55 , C07K16/40 , G01N33/573 , G01N33/577 , C40B40/08
CPC分类号： C12N9/18 , C07K16/40 , C12Y301/01047 , C40B40/08 , G01N33/573 , G01N33/577
摘要：本发明涉及一种人的血小板激活因子乙酰水解酶IB亚基γ突变蛋白及其应用，将若干白血病患者、脑出血患者作为研究病例，对病例进行基因检测并分析，确定出人的血小板激活因子乙酰水解酶IB亚基γ的突变蛋白，根据该人的血小板激活因子乙酰水解酶IB亚基γ突变蛋白制备基因芯片、单克隆抗体和ELISA试剂盒，为白血病、脑出血的基因诊断提供指引作用，实现白血病、脑出血的诊断和治疗。

2. 发明公开

CN107969127A APOA-1融合多肽及相关组合物和方法有权
公开(公告)号：CN107969127A
公开(公告)日：2018-04-27
申请号：CN201680051589.5
申请日：2016-09-06
申请人：赛瑞品股份有限公司
发明人： M·S·海登-莱德贝特 , J·A·莱德贝特 , V·莫特斯
IPC分类号： C07K14/775 , C12N9/18 , C12N9/22
CPC分类号： C07K14/775 , C07K2319/30 , C12N9/18 , C12N9/22 , C12N15/62 , C12Y301/01002 , C12Y301/01047 , C12Y301/08001 , C12Y301/27005
摘要：公开了涉及ApoA-1融合多肽的组合物和方法。融合多肽包含对应于ApoA-1多肽或ApoA-1模拟物的第一多肽区段，并且还可以包含二聚化结构域，例如像Fc区，其通常经由柔性接头在羧基末端与所述第一多肽区段连接。在一些实施方案中，融合多肽进一步包含羧基末端位于第一多肽区段并赋予第二生物学活性的第二多肽区段(例如RNA酶、对氧磷酶、血小板活化因子乙酰水解酶、胆固醇酯转运蛋白、卵磷脂胆固醇酰基转移酶、或与β淀粉样蛋白特异性结合的多肽)。还公开了包含本文公开的第一和第二ApoA-1融合多肽的二聚体蛋白。融合多肽和二聚体蛋白可用在治疗方法中。

3. 发明申请

US20120328596A1 USE OF PLATELET ACTIVATING FACTOR ACETYLHYDROLASE AS A BIOMARKER FOR ANAPHYLAXIS 有权
标题翻译：平板激活因子乙酰胆碱酯酶作为生物标记物的应用
公开(公告)号：US20120328596A1
公开(公告)日：2012-12-27
申请号：US13602289
申请日：2012-09-03
申请人： Peter VADAS
发明人： Peter VADAS
IPC分类号： G01N21/76 , A61K38/46 , A61P11/00 , C12N9/18
CPC分类号： G01N33/86 , A61K38/465 , C12Q1/56 , C12Y301/01047 , G01N2800/24
摘要： The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.
摘要翻译：本发明提供血小板激活因子乙酰水解酶（PAF-AH）活性作为受试者中严重或致命性过敏反应的生物标志物的用途。 PAF-AH活性水平与严重或致命性过敏反应的易感性呈负相关。该用途包括测定来自受试者的样品中的PAF-AH活性并将测量的活性与参考值进行比较，其中相对于所述参考水平的PAF-AH活性的较低水平的测量的PAF-AH活性指示存在或易感性在主题中发生严重或致命的过敏反应。还提供了治疗或预防受试者中严重或致命性过敏反应的方法。该方法包括通过给予受试者PAF-AH和/或PAF受体拮抗剂来增加受试者的血小板活化因子乙酰水解酶（PAF-AH）浓度。还提供了用于治疗严重或致命过敏反应的组合物。

4. 发明申请

US20140283157A1 LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：脂蛋白相关磷酸酶A2抗体组合物及使用方法
公开(公告)号：US20140283157A1
公开(公告)日：2014-09-18
申请号：US13839041
申请日：2013-03-15
申请人： diaDexus, Inc.
发明人： Paul Levi Miller , Laura Corral
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C12N9/20 , C12Y301/01047 , G01N33/573 , G01N2333/92
摘要： The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
摘要翻译：本发明提供了与Lp-PLA2结合的分离的抗Lp-PLA2抗体。本发明还包括包含抗Lp-PLA2抗体的组合物。这些组合物可以在制品或试剂盒中提供。本发明的另一方面是编码抗Lp-PLA2抗体的分离的核酸，以及包含分离的核酸的表达载体。还提供产生抗Lp-PLA2抗体的细胞。本发明包括生产抗Lp-PLA2抗体的方法。本发明的其它方面是检测受试者中的Lp-PLA2的方法。

5. 发明授权

US08562982B2 Use of platelet activating factor acetylhydrolase as a biomarker for anaphylaxis 有权
标题翻译：使用血小板激活因子乙酰水解酶作为过敏反应的生物标志物
公开(公告)号：US08562982B2
公开(公告)日：2013-10-22
申请号：US13602289
申请日：2012-09-03
申请人： Peter Vadas
发明人： Peter Vadas
IPC分类号： A61K38/46 , A61K38/43
CPC分类号： G01N33/86 , A61K38/465 , C12Q1/56 , C12Y301/01047 , G01N2800/24
摘要： The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.
摘要翻译：本发明提供血小板激活因子乙酰水解酶（PAF-AH）活性作为受试者中严重或致命性过敏反应的生物标志物的用途。 PAF-AH活性水平与严重或致命性过敏反应的易感性呈负相关。该用途包括测定来自受试者的样品中的PAF-AH活性并将测量的活性与参考值进行比较，其中相对于所述参考水平的PAF-AH活性的较低水平的测量的PAF-AH活性指示存在或易感性在主题中发生严重或致命的过敏反应。还提供了治疗或预防受试者中严重或致命性过敏反应的方法。该方法包括通过给予受试者PAF-AH和/或PAF受体拮抗剂来增加受试者的血小板活化因子乙酰水解酶（PAF-AH）浓度。还提供了用于治疗严重或致命过敏反应的组合物。

6. 发明授权

US09000132B2 Lipoprotein-associated phospholipase A2 antibody compositions and methods of use 有权
标题翻译：脂蛋白相关磷脂酶A2抗体组合物和使用方法
公开(公告)号：US09000132B2
公开(公告)日：2015-04-07
申请号：US13956139
申请日：2013-07-31
申请人： diaDexus, Inc.
发明人： Paul Levi Miller , Laura Corral
IPC分类号： C07K16/40 , C12N9/20 , G01N33/573
CPC分类号： C07K16/40 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C12N9/20 , C12Y301/01047 , G01N33/573 , G01N2333/92
摘要： The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
摘要翻译：本发明提供了与Lp-PLA2结合的分离的抗Lp-PLA2抗体。本发明还包括包含抗Lp-PLA2抗体的组合物。这些组合物可以在制品或试剂盒中提供。本发明的另一方面是编码抗Lp-PLA2抗体的分离的核酸，以及包含分离的核酸的表达载体。还提供产生抗Lp-PLA2抗体的细胞。本发明包括生产抗Lp-PLA2抗体的方法。本发明的其它方面是检测受试者中的Lp-PLA2的方法。

7. 发明授权

US08257697B2 Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis 有权
标题翻译：使用血小板激活因子乙酰水解酶作为过敏反应的生物标志物
公开(公告)号：US08257697B2
公开(公告)日：2012-09-04
申请号：US12262949
申请日：2008-10-31
申请人： Peter Vadas
发明人： Peter Vadas
IPC分类号： A61K38/46 , C12Q1/34
CPC分类号： G01N33/86 , A61K38/465 , C12Q1/56 , C12Y301/01047 , G01N2800/24
摘要： A method for determining a patient's susceptibility to anaphylaxis comprises assaying the activity of platelet activating factor acetylhydrolase (PAF-AH) activity and comparing the measured activity to a reference value, wherein the level of PAF-AH activity inversely correlates with the susceptibility to anaphylaxis. The method further comprises determining the severity of anaphylaxis by correlating the degree of reduced PAF-AH activity to the reference value. The method further comprises measuring IgE concentration and comparing the measured concentration to a reference concentration. The invention further provides a method for diagnosing anaphylaxis in a patient comprising measuring the serum concentration of platelet activating factor (PAF) and comparing the measured concentration to a reference value, wherein the concentration of PAF correlates directly with severity of anaphylaxis. The invention also provides a kit for performing the required assay or assays.
摘要翻译：用于确定患者对过敏性易感性的方法包括测定血小板活化因子乙酰水解酶（PAF-AH）活性的活性并将测量的活性与参考值进行比较，其中PAF-AH活性水平与过敏反应的易感性成反比。该方法还包括通过将降低的PAF-AH活性的程度与参考值相关联来确定过敏反应的严重程度。该方法还包括测量IgE浓度并将测量的浓度与参考浓度进行比较。本发明还提供了一种用于诊断患者过敏反应的方法，包括测量血小板活化因子（PAF）的血清浓度并将测量的浓度与参考值进行比较，其中PAF的浓度与过敏反应的严重程度直接相关。本发明还提供了用于进行所需测定或测定的试剂盒。

8. 发明公开

EP0948605A1 TRUNCATED PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE 失效
标题翻译：简明乙酰血小板活化因子
公开(公告)号：EP0948605A1
公开(公告)日：1999-10-13
申请号：EP97937217.0
申请日：1997-08-13
申请人： ICOS CORPORATION
发明人： COUSENS, Lawrence, S. , EBERHARDT, Christine, D. , GRAY, Patrick , TRONG, Hai, Le , TJOELKER, Larry, W. , WILDER, Cheryl, L.
IPC分类号： C12N , C12N15 , A61K38 , A61P11 , A61P25 , A61P27 , C12N1 , C12N5 , C12N9 , C12R1
CPC分类号： C12N9/18 , A61K38/00 , C12Y301/01047
摘要： The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

9. 发明申请

US20150203590A1 LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：脂蛋白相关磷酸酶A2抗体组合物及使用方法
公开(公告)号：US20150203590A1
公开(公告)日：2015-07-23
申请号：US14678562
申请日：2015-04-03
申请人： Paul Levi MILLER , Laura CORRAL
发明人： Paul Levi MILLER , Laura CORRAL
IPC分类号： C07K16/40 , G01N33/573
CPC分类号： C07K16/40 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C12N9/20 , C12Y301/01047 , G01N33/573 , G01N2333/92
摘要： The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
摘要翻译：本发明提供了与Lp-PLA2结合的分离的抗Lp-PLA2抗体。本发明还包括包含抗Lp-PLA2抗体的组合物。这些组合物可以在制品或试剂盒中提供。本发明的另一方面是编码抗Lp-PLA2抗体的分离的核酸，以及包含分离的核酸的表达载体。还提供产生抗Lp-PLA2抗体的细胞。本发明包括生产抗Lp-PLA2抗体的方法。本发明的其它方面是检测受试者中的Lp-PLA2的方法。

10. 发明申请

US20140275485A1 LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE 有权
公开(公告)号：US20140275485A1
公开(公告)日：2014-09-18
申请号：US13956139
申请日：2013-07-31
申请人： diaDexus, Inc.
发明人： Paul Levi MILLER , Laura CORRAL
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C12N9/20 , C12Y301/01047 , G01N33/573 , G01N2333/92
摘要： The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式